GSK halts Promacta trial on blood clot concerns; Resverlogix modifies trial enrollment; Lee Rauch named new CEO of Nuon;

 @FierceBiotech: Troubled Genzyme launches probe into insider trading claims. Article | Follow @FierceBiotech

 @JohnCFierce: 15 VC-backed companies traded hands last week. So is the party back on yet? Nope. Report  | Follow @JohnCFierce

> The FDA has noted that a clinical trial of GlaxoSmithKline's Promacta was halted after researchers spotted a higher rate of blood clots among patients taking the drug compared with the placebo arm. Promacta had been in a trial for chronic immune idiopathic thrombocytopenic purpura triggered by no known cause. The trial involved patients with ITP triggered by liver damage. Story

> Resverlogix says it has halted enrollment in a clinical trial to test a treatment for thickening of the arteries. The developer says it wants to modify its enrollment procedures, news that sent its shares down about 7 percent. Report

> Nuon Therapeutics named Lee Rauch president and CEO. Recently, she held the position of acting head of corporate development for Onyx Pharmaceuticals. Nuon release

> Colorado State University has opened a new, $53 million life sciences incubator. Report

> Irvine, CA-based Cobalis has named Martin Marion as its new chief executive officer. Cobalis release

And Finally... Walgreens has dropped the idea of selling a genetic home test after the FDA opened an investigation of the supplier, Pathway Genetics, and its product. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.